Related Experiment Videos
Nanodrugs Detonate Lysosome Bombs.
Yuting Xiang1, Niansheng Li1, Min Liu2,3
1Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Frontiers in Pharmacology
|June 3, 2022
Summary
Nanodrugs can selectively trigger lysosomal membrane permeabilization (LMP) in cancer cells, offering a powerful strategy for targeted cancer therapy with minimal side effects. This review explores nanodrugs-induced LMP approaches for enhanced anticancer drug delivery.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Biology
Background:
- Lysosomes contain potent hydrolases and substrates capable of destroying cancer cells.
- Traditional small molecule drugs targeting lysosomes exhibit significant side effects due to lack of cell specificity.
- Current research often focuses on mild lysosomal membrane permeabilization (LMP) for drug release, overlooking lysosomes' full destructive potential.
Purpose of the Study:
- To comprehensively review recent advances in nanodrugs-induced lysosomal membrane permeabilization (LMP) for cancer therapy.
- To elucidate various nanodrug strategies for selectively inducing LMP in cancer cells.
- To analyze the future prospects and challenges of nanodrugs-induced LMP.
Main Methods:
- Summarizing recent literature on nanodrugs-induced LMP.
- Categorizing and describing different nanodrug-induced LMP strategies.
- Analyzing the potential and limitations of these therapeutic approaches.
Main Results:
- Nanodrugs offer diverse properties for designing targeted therapies.
- Selective cancer cell LMP induction by nanodrugs can lead to high efficacy and low toxicity.
- Key strategies include nanoparticle aggregation-induced LMP, chemodynamic therapy (CDT)-induced LMP, and magnetic field-induced LMP.
Conclusions:
- Nanodrugs-induced LMP represents a promising strategy for developing highly effective and specific cancer therapeutics.
- Overcoming challenges in nanodrug design and delivery is crucial for clinical translation.
- This review provides a unique perspective for designing novel lysosome-targeting anticancer drugs.